Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 20;2(1):e000089.
doi: 10.1136/lupus-2015-000089. eCollection 2015.

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome

Maria Dall'Era  1 , Victoria Levesque  2 , Neil Solomons  3 , Matt Truman  4 , David Wofsy  5
Affiliations

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome

Maria Dall'Era et al. Lupus Sci Med. .

Abstract

Objective: To identify factors associated with clinical outcome in patients with lupus nephritis.

Methods: Data from the Aspreva Lupus Management Study (ALMS) were analysed. Using multivariate analysis, we assessed the prognostic value of demographic, clinical, laboratory and histopathological features on the frequency of either complete remission (CR) or treatment failure (TF) during the maintenance phase.

Results: Among the 370 subjects who entered the trial (complete population), non-Hispanic ethnicity was associated with a higher likelihood of CR (OR=2.0). Several factors were independently associated with a greater likelihood of TF, including: (1) anti-double-stranded DNA (anti-dsDNA) at trial entry (OR=12.7), (2) failure to reduce anti-dsDNA within 8 weeks (OR=2.9) and (3) failure to reduce urine protein:creatinine ratio (UP/C) by ≥25% within 8 weeks (OR=2.6). Among the 227 subjects who entered the maintenance phase (maintenance population), baseline estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m(2) was associated with a greater likelihood of CR (OR=2.0), and UP/C >1 at the end of induction was associated with a lower likelihood of CR (OR=0.3). Induction treatment with intravenous cyclophosphamide (IVC) was associated with a lower likelihood of TF (OR=0.5), while lack of treatment with antimalarials (OR=2.4), failure to reduce anti-dsDNA during the first 8 weeks of induction (OR=3.5), failure to reduce UP/C during the first 8 weeks of induction (OR=2.1) and anti-dsDNA positivity at the end of induction (OR=8.3) were independently associated with a greater likelihood of TF.

Conclusions: This analysis demonstrates that levels of anti-dsDNA and UP/C during induction treatment are independently associated with renal outcome over the ensuing 3 years in both the complete and maintenance populations. Ethnicity is associated with renal outcome in just the complete population, and eGFR, induction treatment and treatment with antimalarials are associated with renal outcome in just the maintenance population.

Keywords: Autoantibodies; DMARDs (synthetic); Lupus Nephritis.

PubMed Disclaimer

References

    1. Faurschou M, Dreyer L, Kamper A et al. . Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62:873–80. doi:10.1002/acr.20116 - DOI - PubMed
    1. Dall'Era M, Stone D, Levesque V et al. . Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res 2011;63:351–7. doi:10.1002/acr.20397 - DOI - PubMed
    1. Appel GB, Contreras G, Dooley MA et al. . Mycophenolate mofetil versus cyclophosphamide for the induction treatment of lupus nephritis. J Am Soc Nephrol 2009;49:128–40. - PMC - PubMed
    1. Sinclair A, Appel G, Dooley MA et al. . Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007;16:972–80. doi:10.1177/0961203307084712 - DOI - PubMed
    1. Dooley MA, Jayne D, Ginzler EM et al. . Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1186–95. doi:10.1056/NEJMoa1014460 - DOI - PubMed

LinkOut - more resources